Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-01-26FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for sildenafil citrate (generic) filed by Mylan Pharmaceuticals Inc. The action pertains to a supple…
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension [Phase 3]
Phase 3 clinical trial update for epoprostenol for injection (EFI/ACT-385781A) in pulmonary arterial hypertension; the study completed and r…
-
CLINICAL_TRIALS trial_result · 2014-12-29Clinical Trial Update: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease [NA]
Clinical trial evaluating iloprost for pulmonary hypertension in adults with congenital heart disease was terminated; results were posted in…
-
FDA approval · 2014-12-22FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for REMODULIN (treprostinil) submitted by United Therapeutics Corporation. The approval finalize…
-
CLINICAL_TRIALS research · 2014-11-21Clinical Trial Update: Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension [NA]
This clinical trial update discusses a safety procedure that combines pulmonary artery denervation with pulmonary vein isolation and ganglio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-10-29FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc. The action involves updating the produ…
-
FDA approval · 2014-10-06FDA Approved: ORENITRAM — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for ORENITRAM (treprostinil) submitted by United Therapeutics Corporation.
-
FDA approval · 2014-09-26FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, Inc.
-
CLINICAL_TRIALS withdrawal · 2014-09-10Clinical Trial Update: (-)-Epicatechin and Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 clinical trial evaluating (-)-Epicatechin for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS research · 2014-09-08Clinical Trial Update: Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension [EARLY_Phase 1]
A Phase 1 clinical trial update evaluating whether HIV protease inhibitors can reduce inflammation and improve cardiopulmonary hemodynamics …
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Nitric Oxide, GeNO Nitrosyl Delivery System [Phase 2]
Phase 2 trial of the GeNO Nitrosyl Delivery System for pulmonary arterial hypertension has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-08-29Clinical Trial Update: Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
A completed clinical trial evaluated whether educational training via INSIGHT improves adherence to inhaled treprostinil (Ventavis) in patie…
-
CLINICAL_TRIALS trial_result · 2014-08-22Clinical Trial Update: Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension [Phase 2]
The document reports Phase 2 trial results on Terbogrel for primary pulmonary hypertension, focusing on safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2014-08-22Clinical Trial Update: Safety of Terbogrel in Patients With Primary Pulmonary Hypertension [Phase 2]
Phase 2 safety update on terbogrel in patients with pulmonary arterial hypertension; the trial was terminated.
-
FDA approval · 2014-08-21FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved Viatris Specialty LLC's supplemental application for REVATIO (sildenafil citrate), enabling changes to the drug's approved …
-
FDA approval · 2014-08-15FDA Approved: SILDENAFIL — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for sildenafil submitted by Torrent Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2014-08-12Clinical Trial Update: Oral Iron Supplementation in Pulmonary Hypertension [NA]
A completed clinical trial evaluating oral iron supplementation in patients with pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2014-08-11Clinical Trial Update: A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children [Phase 3]
Long-term safety data from a Phase 3 extension study of sildenafil citrate in children with pulmonary arterial hypertension has been complet…
-
CLINICAL_TRIALS trial_result · 2014-08-11Clinical Trial Update: Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension [Phase 4]
Phase 4 trial update examining the safety of switching patients from bosentan to ambrisentan in pulmonary arterial hypertension; results hav…
-
CLINICAL_TRIALS withdrawal · 2014-08-07Clinical Trial Update: Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers [Phase 1]
A Phase 1 dose-escalation study evaluating safety, maximum tolerated dose and pharmacokinetics of a single subcutaneous dose of TransCon PEG…
-
FDA approval · 2014-08-01FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for TYVASO (treprostinil) from United Therapeutics Corporation. This action constitutes a supple…
-
FDA approval · 2014-07-02FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA has approved a supplemental application for LETAIRIS (ambrisentan) by Gilead Sciences. This action updates the product labeling and/…
-
FDA approval · 2014-06-11FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc., approving a supplemental submiss…
-
CLINICAL_TRIALS trial_result · 2014-06-03Clinical Trial Update: Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension [Phase 1]
Phase 1 clinical trial evaluating dichloroacetate (DCA) for pulmonary arterial hypertension has completed.
-
FDA label_change · 2014-05-20FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
FDA approved a supplemental application for Tyvaso (treprostinil) submitted by United Therapeutics Corporation to modify its label and/or in…